Publications by authors named "Kassim Rahawi"
Article Synopsis
- - Upadacitinib (UPA) is a JAK inhibitor effective for moderate-to-severe rheumatoid arthritis, showing a good safety profile in clinical trials that analyzed laboratory parameter changes.
- - The study pooled data from six trials involving over 3200 patients, revealing changes in blood counts and liver enzymes, with most adverse events, like anemia and neutropenia, occurring at similar rates compared to other treatments.
- - Overall findings indicate that UPA has long-term safety and efficacy, with very few patients discontinuing treatment due to lab-related issues.
Article Synopsis
- This study examines the impact of consistent use of biologic treatments for hidradenitis suppurativa (HS) on the need for surgical procedures, systemic medications, and overall healthcare use.
- It analyzed data from the UNITE registry, which followed HS patients for four years to observe their treatment patterns and outcomes.
- The results showed a decrease in the need for surgical interventions, systemic medications, and hospital visits after starting consistent biologic therapy, suggesting it may help reduce disease severity and healthcare demands in HS patients.
To our knowledge, the effect of plasmapheresis on the anti-factor Xa activity of enoxaparin has never been reported. We describe a 13-year-old, obese (92-kg) girl who was treated with enoxaparin for a pulmonary embolism while receiving plasmapheresis for suspected autoimmune encephalitis and who experienced clinically significant reductions in anti-factor Xa activity after plasmapheresis. She received five courses of plasmapheresis, with the final two administered during treatment with enoxaparin.
View Article and Find Full Text PDF